{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:26:59Z","timestamp":1783088819135,"version":"3.54.6"},"reference-count":27,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","award":["J85I2000009005"],"award-info":[{"award-number":["J85I2000009005"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,10,17]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate the use of maintenance immunosuppressive treatments following liver transplantation and to compare their risk\u2013benefit profiles in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective multicentrer cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Four Italian regions (Lombardy, Veneto, Lazio, Sardinia).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were integrated from the national transplant information system and administrative claims data from four Italian regions. All adults who underwent incident liver transplantation between 2009 and 2019 were identified and categorised into two groups: cirrhosis or hepatocellular carcinoma (HCC). The trend of immunosuppressive treatment over years was analysed, and their effectiveness\/safety profiles were compared using multivariate Cox models (HR; 95% CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Mortality, transplant reject\/graft failure, incidence of severe infections, cancer, diabetes, major adverse cardiovascular events and lipid-modifying agents use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study comprised 750 subjects in the cirrhosis cohort and 1159 in the HCC cohort. Over the study years, there was a decline in the use of cyclosporine-CsA, while combination therapy involving tacrolimus with other drugs increased compared with monotherapy. Overall, tacrolimus monotherapy use was slightly over 40% in both groups, followed by tacrolimus+mycophenolate (39.5%-cirrhosis; 30.6%-HCC) and tacrolimus+molecular target of rapamycin inhibitors (mTORi) (8.5%-cirrhosis; 13.3%-HCC). No significant differences emerged in risk\u2013benefit profile of different tacrolimus-based therapies, except for a higher risk of mortality in cirrhosis subjects under tacrolimus monotherapy compared with tacrolimus+mycophenolate (HR: 2.07; 1.17 to 3.65).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study highlights a shift over time in postliver transplant therapeutic patterns, favouring the use of tacrolimus in combination with mycophenolate or mTORi, rather than monotherapy. Moreover, a potential association between tacrolimus monotherapy and increased mortality in the cirrhosis cohort was identified. Further research is warranted to investigate these findings more deeply and to optimise treatment strategies for liver transplant recipients.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087373","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T18:15:56Z","timestamp":1731435356000},"page":"e087373","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Maintenance immunosuppressive therapy in liver transplantation: results from CESIT study, an Italian retrospective cohort study"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4558-0921","authenticated-orcid":false,"given":"Arianna","family":"Bellini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Finocchietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Cesare","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-4238","authenticated-orcid":false,"given":"Marco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-1346","authenticated-orcid":false,"given":"Stefania","family":"Spila Alegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pierobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Ferroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Zanforlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ledda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Addis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8286-443X","authenticated-orcid":false,"given":"Valeria","family":"Belleudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"2024121219333364000_14.11.e087373.1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.13358"},{"key":"2024121219333364000_14.11.e087373.2","article-title":"Immunosuppression in liver transplant","volume":"46\u201347","author":"Di Maira","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2024121219333364000_14.11.e087373.3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.27538","article-title":"Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study","volume":"61","author":"\u00c5berg","year":"2015","journal-title":"Hepatology"},{"key":"2024121219333364000_14.11.e087373.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03126.x"},{"key":"2024121219333364000_14.11.e087373.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.006"},{"key":"2024121219333364000_14.11.e087373.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.06.007"},{"key":"2024121219333364000_14.11.e087373.7","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002147"},{"key":"2024121219333364000_14.11.e087373.8","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2022.1060621","article-title":"Temporal and spatial variability of immunosuppressive therapies in transplant patients: An observational study in Italy","volume":"1","author":"Marino","year":"2022","journal-title":"Front Transplant"},{"key":"2024121219333364000_14.11.e087373.9","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10091-5"},{"key":"2024121219333364000_14.11.e087373.10","unstructured":"Massari M , Alegiani SS , Cas R , et al . Istituto Superiore Di Sanit\u00e0 \u201cTheShinISS\u201d: Un Applicativo Open-Source per La Conduzione Di Analisi Distribuite in Studi Di Farmacoepidemiologia Di Tipo Multi-Database. 2020."},{"key":"2024121219333364000_14.11.e087373.11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.959267","article-title":"An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project","volume":"13","author":"Belleudi","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024121219333364000_14.11.e087373.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104"},{"key":"2024121219333364000_14.11.e087373.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11196-2"},{"key":"2024121219333364000_14.11.e087373.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.03.128"},{"key":"2024121219333364000_14.11.e087373.15","first-page":"599","article-title":"Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy","volume":"42","author":"Nelson","year":"2022","journal-title":"Am Soc Transplant, Int Soc Heart Lung Transplant Pharmacotherapy"},{"key":"2024121219333364000_14.11.e087373.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01360.x"},{"key":"2024121219333364000_14.11.e087373.17","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.3390\/curroncol30060421","article-title":"The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma","volume":"30","author":"Todeschini","year":"2023","journal-title":"Curr Oncol"},{"key":"2024121219333364000_14.11.e087373.18","unstructured":"Centro Nazionale Trapianti . Valutazione di Qualit\u00e0 dell\u2019attivit\u00e0 del trapianto di fegato 2000-2020, Available: https:\/\/trapianti.sanita.it\/statistiche\/attivita\/2023_D_QUALITA_ORGANI_FEGATO_00-20.pdf"},{"key":"2024121219333364000_14.11.e087373.19","first-page":"115","article-title":"Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience","volume":"58","author":"Jim\u00e9nez-Romero","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"2024121219333364000_14.11.e087373.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.04.045"},{"key":"2024121219333364000_14.11.e087373.21","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/TP.0000000000003998","article-title":"De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference","volume":"106","author":"Colmenero","year":"2022","journal-title":"Transplantation"},{"key":"2024121219333364000_14.11.e087373.22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/TP.0000000000001438","article-title":"Use of Everolimus in Liver Transplantation: Recommendations From a Working Group","volume":"101","author":"De Simone","year":"2017","journal-title":"Transplantation"},{"key":"2024121219333364000_14.11.e087373.23","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/845438","article-title":"The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence","volume":"2014","author":"Klintmalm","year":"2014","journal-title":"J Transplant"},{"key":"2024121219333364000_14.11.e087373.24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.mayocp.2012.02.021","article-title":"Long-term medical management of the liver transplant recipient: what the primary care physician needs to know","volume":"87","author":"Singh","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"2024121219333364000_14.11.e087373.25","unstructured":"Regolamento 2016\/679-GDR del Parlamento Europeo e del Consiglio del. 2016."},{"key":"2024121219333364000_14.11.e087373.26","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/apt.15253","article-title":"Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2024121219333364000_14.11.e087373.27","doi-asserted-by":"crossref","unstructured":"Bennie M , Kurdi A , Mueller T . Using administrative data from public health and drug programs. In: Encyclopedia of evidence in pharmaceutical public health and health services research in pharmacy. Cham: Springer, 2022.","DOI":"10.1007\/978-3-030-50247-8_61-1"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T03:42:00Z","timestamp":1734061320000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,12]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/bmjopen-2024-087373"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087373","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}